NOT-TR-24-001: Notice of Termination of PAR-21-340 "Limited Competition: High Impact Specialized Innovation Programs in Clinical and Translational Science for UM1 CTSA Hub Awards (RC2 Clinical Trial Not Allowed)

Notice of Termination of PAR-21-340 "Limited Competition: High Impact Specialized Innovation Programs in Clinical and Translational Science for UM1 CTSA Hub Awards (RC2 Clinical Trial Not Allowed)”

Notice Number:

NOT-TR-24-001

Key Dates

Release Date:

November 7, 2023

Related Announcements

September 17, 2021 - Limited Competition: High Impact Specialized Innovation Programs in Clinical and Translational Science for UM1 CTSA Hub Awards (RC2 Clinical Trials Not Allowed). See NOFO PAR-21-340.

November 7, 2023, - Limited Competition: High Impact Specialized Innovation Programs in Clinical and Translational Science for UM1 CTSA Hub Awards (RC2 Clinical Trials Optional). See NOFO PAR-24-054 .

Issued by

National Center for Advancing Translational Sciences (NCATS)

Purpose

Effective immediately, the Notice of Funding Opportunity PAR-21-340 "Limited Competition: High Impact Specialized Innovation Programs in Clinical and Translational Science for UM1 CTSA Hub Awards (RC2 Clinical Trials Not Allowed)” is terminated. Applications submitted to PAR-21-340 will not be reviewed. NIH plans to re-issue (or has re-issued) this Notice of Funding Opportunity as PAR-24-054 - "Limited Competition: High Impact Specialized Innovation Programs in Clinical and Translational Science for UM1 CTSA Hub Awards (RC2 Clinical Trial Optional)”.

Inquiries

Please direct all inquiries to:

Pablo Cure, M.D., M.P.H.
National Center for Advancing Translational Sciences (NCATS)
Telephone: 301-827-2014
Email: RC2NOFO@nih.gov